Kiora Pharmaceuticals Inc. (KPRX)
KPRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1372514/000137251426000024/0001372514-26-000024-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | KPRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001372514 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$10.8M |
| Operating income | -$12.8M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $8.7M |
| Total assets | $24.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The factors described above have caused management to determine there is substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $5.6M cash; operating cash flow -$1.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 4,424,387 (2026-11-10); 3,677,935 a year earlier; 7,689,240 three years earlier. 3y figure adjusted for splits (1-for-9 overall). | Cover page 2026-11-10 |
| Reverse splits, 3 years | 1; latest 1-for-9 on 2024-06-11 | Source 2024-06-11 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Haskell & White LLP, Irvine, California, United States | PCAOB Form AP 2026-04-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.0M | -$1.7M | -$558K | $5.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$2.1M | -$1.9M | $7.1M | No debt tags | Needs four quarters | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | Not filed | -$2.4M | -$3.2M | $11.0M | No debt tags | Needs four quarters | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $0 | -$6.5M | -$2.2M | $8.7M | No debt tags | $0 | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | $0 | $27K | -$1.3M | $5.5M | No debt tags | $0 | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $0 | -$2.2M | -$3.8M | $1.0M | No debt tags | $0 | 10-Q 2025-08-08 |
| Q1 2025 2025-03-31 | $0 | -$2.2M | -$2.7M | $3.8M | No debt tags | $20K | 10-Q 2025-05-09 |
| Q4 2024 2024-12-31 | $0 | -$4.2M | -$2.3M | $3.8M | No debt tags | $16.0M | 10-K 2026-03-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-05-28 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 929 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.6% |
| 1 month | -50.2% |
| 3 months | -52.5% |
| Year to date | -37.6% |
| 1 year | -44.0% |
| From 52-week high | -57.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BGMS | Bio Green Med Solution Inc. | $0.6502 | +1.55% | $4.3M |
| NCNA | NuCana plc American Depositary Share | $0.8631 | -7.46% | $4.4M |
| SKYE | Skye Bioscience Inc. | $1.06 | -2.29% | $4.7M |
| TRAW | Traws Pharma Inc. | $0.2600 | +3.59% | $4.0M |
| CANF | Can-Fite Biopharma Ltd | $1.56 | +9.86% | $4.7M |
| PCSA | Processa Pharmaceuticals Inc. | $1.72 | -7.53% | $4.8M |
| PULM | Pulmatrix Inc. | $1.33 | +2.31% | $4.9M |
| IMNN | Imunon Inc. | $0.5940 | -5.56% | $3.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier